Doxazosin Mesylate is a quinazoline derivative and selective α1-adrenoceptor antagonist widely used in the management of benign prostatic hyperplasia (BPH) and hypertension. The development of reliable, accurate and sensitive analytical methods is essential for the identification, quantification and quality control of Doxazosin Mesylate in bulk drug substances, pharmaceutical dosage forms and biological matrices. The present review summarizes the physicochemical and pharmacological characteristics of Doxazosin Mesylate and provides a comprehensive overview of the analytical methods reported for its determination. Various analytical techniques, including UV-visible spectrophotometry, reverse-phase high-performance liquid chromatography (RP-HPLC), stability-indicating HPLC, high-performance thin-layer chromatography (HPTLC) and ultra-performance liquid chromatography (UPLC), have been reported for the estimation of Doxazosin Mesylate. The reviewed spectrophotometric methods commonly employ detection around 245nm, while chromatographic methods utilize different stationary phases and mobile-phase compositions depending on the analytical objective. The reported methods have been evaluated for important validation parameters such as linearity, accuracy, precision, specificity, sensitivity, robustness, limit of detection and limit of quantification. Stability-indicating methods have also demonstrated the ability to separate Doxazosin Mesylate from degradation products generated under different stress conditions. Overall, the available analytical approaches provide useful tools for routine quality control and pharmaceutical analysis of Doxazosin Mesylate. The review highlights the evolution of analytical methodologies and provides a useful reference for the selection and further development of simple, rapid, accurate, precise and stability-indicating methods for Doxazosin Mesylate.